Q4 2022 Results
Company overview
Financial review
2023 priorities
Appendix
Focused on five core Therapeutic Areas that have the largest
growth potential and leverage our existing assets/expertise
STRATEGY
Select examples¹
Disease
areas
(selected)
☐
Cardiovascular
■ Heart failure & hypertension
Atherosclerosis
Commercial
assets
sacubitril/valsartan
Immunology
■ Psoriasis
Psoriatic arthritis
Spondylitis/Spondylarthritis
Hidradenitis suppurativa
■ CSU
Sjögren's / SLE/LN
Neuroscience
☐
Multiple sclerosis
Spinal muscular atrophy
Neurodegeneration, including
Parkinson's, ALS
Solid Tumors
■ Prostate cancer
■ Breast and Women's cancer
Lung cancer
Entresto LEQVIO Cosentyx LARIS
secukinumab
(canakinumab)
Kesimpta
(ofatumumab)
zolgensma
2
Xolair
Omalizumab
(siponimod) tablets
MAYZENT aimovig
ferenumab-aco M
GILENYA
Cingolimod
KISQALI
ribociclib.
Tafinlar +Mekinist
(deelenib
(ne)
Hematology
"
Non-Hodgkin's Lymphoma
Non-malignant hematological -
Immune thrombocytopenia
■ Acute myeloid leukemia /
Myelodysplastic syndrome
PLUVICTO
◆ PIQRAY
(alpelis b) tablets
x
PROMACTA
(eltrombopag)
KYMRIAH
(tisagenlecleucel)
SCEMBLIX®
(asciminib) 20mg 4 ng tables
ⒸJAKAVI
ruxolitinib
Pipeline
Iptacopan (LNP023)
assets and
C3G, IgAN
opportunities
Pelacarsen³ (TQJ230)
CVRR-Lp(a)
Leqvio
CVRR-LDLC
XXB750
HFPEF, rHT
Cosentyx
Multiple indications
Remibrutinib (LOU064)
CSU
lanalumab (VAY736)
Sjögren's, SLE, LN
Ligelizumab (QGE031)
Food Allergy
Remibrutinib (LOU064)
MS
OAV101
SMA IT
DLX3134
Parkinson's
Kisqali
Adjuvant HR+/HER2- BC
JDQ433
NSCLC
NIS793
1L mPDAC / 1L MCRC
Pluvicto
Prostate cancer
Iptacopan (LNP023)
PNH, AHUS
lanalumab (VAY736)
Multiple indications
YTB323
Non-Hodgkin's Lymphoma
FY Sales
USD5
4.8bn
7.3bn
5.1bn
4.7bn
6.5bn
1. TA-x (incl. Ophtha, Resp and other assets) not included in the above list. 2. AimovigⓇ is commercialized by Novartis ex-US/Japan. 3. Pelacarsen is licensed from lonis Pharmaceuticals, Inc. 4. DLX313 is Novartis program name for
UCB0599. 5. FY 2022 sales for entire Therapeutic Area.
8 Investor Relations | Q4 2022 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation